Integrated Evidence Generation Planning (IEGP) is recognised as a strategic necessity for biopharmaceutical organisations.
A new industry report uncovers the scope of a long-ignored problem in clinical trial operations.
A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.
Read Zühlke’s new white paper, ‘Future Proof Production: Implementing AI in pharmaceutical manufacturing’ today.
The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.
Editor's Picks
